- Home
- Special Topics
- Disease areas
- Cardiovascular diseases
This page brings together the European Medicines Agency's latest information on diseases affecting the heart and blood vessels.
It lists:
the ten newest and recently updated medicines authorised for the treatment of cardiovascular diseases in the European Union (EU);
the most recent opinions on cardiovascular medicines that are pending authorisation by the European Commission (EC);
the latest news and press releases related to cardiovascular diseases;
the Agency's events on cardiovascular topics.
New and recently updated medicines
-
29/06/2012
human
-
11/06/2012
human
-
30/03/2011
human
-
26/07/2012
human
-
26/07/2012
human
-
26/01/2010
human
-
18/04/2011
human
-
20/12/2011
human
-
26/07/2012
human
-
09/06/2011
human
Opinions pending EC decision
-
25/04/2013
human
-
25/04/2013
human
-
25/04/2013
human
-
25/04/2013
human
-
25/04/2013
human
-
25/04/2013
human
-
25/04/2013
human
-
25/04/2013
human
-
25/04/2013
human
-
25/04/2013
human
News
16/05/2013
World Hypertension Day: 17 May 2013
The European Medicines Agency supports World Hypertension Day, which is taking place on Friday 17 May 2013. ... Read more
26/04/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2013
This page provides an overview of the opinions adopted at the April 2013 meeting of the CHMP and other important outcomes. ... Read more
05/04/2013
World Health Day on 7 April 2013: focus on high blood pressure
The European Medicines Agency supports World Health Day, taking place on Sunday 7 April 2013. ... Read more
22/03/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2013
This page provides an overview of the opinions adopted at the March 2013 meeting of the CHMP and other important outcomes. ... Read more
22/03/2013
European Medicines Agency recommends restricting use of cilostazol-containing medicines
The European Medicines Agency’s Committee on Medicinal Products for Human Use (CHMP) has recommended that the use of cilostazol-containing medicines in the treatment of intermittent claudication – a condition where poor blood supply to the leg muscles causes pain and affects the ability to walk – should be restricted with a range of new measures aimed at targeting a patient population in which there are clinical benefits, and at the same time minimising important risks. ... Read more
08/03/2013
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 March 2013
The PRAC welcomed the appointment by the European Commission of one member and alternate each representing healthcare-professional and patient organisations. ... Read more
22/02/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 February 2013
This page provides an overview of the opinions adopted at the February 2013 meeting of the CHMP and other important outcomes. ... Read more
24/01/2013
Novartis Europharm Ltd withdraws its marketing-authorisation application for Ruvise (imatinib mesilate)
The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Ruvise (imatinib mesilate), 100- and 400-mg film-coated tablets. ... Read more
18/01/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 January 2013
This page provides an overview of the opinions adopted at the January 2013 meeting of the CHMP and other important outcomes. ... Read more
18/01/2013
European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed the recommendation to suspend the marketing authorisations of Tredaptive, Pelzont and Trevaclyn (nicotinic acid / laropiprant) used to treat adults with dyslipidaemia (abnormally high blood levels of fats such as triglycerides and cholesterol). ... Read more
Events
29/11/2010
EMA
Expert group meeting on paediatric heart failure
The meeting is identifying priorities for and the optimal design of studies on drug development in paediatric heart failure (HF) for the purpose of the evaluation of paediatric investigation plans. The main topics include new drug classes in the pipeline and priority list for HF drugs in children, types of paediatric HF to be studied, trial design issues and the establishment of a paediatric cardiology network. ... Read more
27/11/2009
CHMP
Committee for Medicinal Products for Human Use (CHMP) Blood Products Working Party (BPWP) stakeholders meeting on normal immunoglobulin for intravenous administration (IVIg) guidance
The BPWP is holding a stakeholder meeting, following the public consultation on the note for guidance on the clinical investigation of IVIg and the core summary of product characteristics for IVIg. ... Read more